

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE
06 JAN -3 PM 12

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Policy Directions Inc.			
2. Address <input type="checkbox"/> Check if different than previously reported 818 CONNECTICUT AVENUE, NW, SUITE 950			
3. Principal Place of Business (if different from line 2) WASHINGTON DC 20006 City: State/zip (or Country)			
4. Contact Name FRANKIE L. TRULL	Telephone (202) 776-0071	E-mail (optional)	5. Senate ID # 31747-238
7. Client Name <input type="checkbox"/> Self Sanofi-Synthelabo Inc. and Aventis Pharmaceuticals Inc., members of the sanofi-aventis Group			6. House ID # 32112017

TYPE OF REPORT 8. Year 2005 Midyear (January 1-June 30) OR Year End (July 1-Dec

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇨ Termination Date December 31, 2005

11. No Lobbyin

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p>12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input checked="" type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this report period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate exp accounting method. See instructions for description of opt</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b) Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code</p>
---	--

Signature Frankie L. Trull Date December 20, 2005

Printed Name and Title FRANKIE L. TRULL, PRESIDENT

0000020193



Registrant Name Policy Directions Inc. Client Name Sanofi-Synthelabo Inc. and Aventis Pharmac

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

Clinical research
Patient protections
FDA policies on OTC drugs

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives
U.S. Senate
FDA

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
FRANKIE L. TRULL	
KATHLEEN (KAY) HOLCOMBE	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Sanofi-aventis is a corporation under French Commercial law, headquartered in Paris, France. Sanofi-Synthelabo Inc. and Pharmaceuticals Inc. are US affiliates and members of the sanofi-aventis group.

Signature Frankie L. Trull Date December 20, 2001

Printed Name and Title FRANKIE L. TRULL, PRESIDENT

3000020194



Registrant Name Policy Directions Inc. Client Name Sanofi-Synthelabo Inc. and Aventis Pharmac

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Medicare payment policy
Medicare drug benefit

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives
U.S. Senate
FDA

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
FRANKIE L. TRULL	
KATHLEEN (KAY) HOLCOMBE	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Sanofi-aventis is a corporation under French Commercial law, headquartered in Paris, France. Sanofi-Synthelabo Inc. and Pharmaceuticals Inc. are US affiliates and members of the sanofi-aventis group.

Signature *Frankie L. Trull* Date December 20, 2005
Printed Name and Title FRANKIE L. TRULL, PRESIDENT

0000020195

